Effect of combination treatment with mitomycin-c and lysosome labilizers on nodular pulmonary metastases.
D003911:Dextrans / Q000008:administration & dosage* / Q000494:pharmacology; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005341:Fibrinolysin / Q000096:biosynthesis; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D008071:Lipoprotein Lipase / Q000097:blood; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008247:Lysosomes / Q000187:drug effects*; D008937:Mitomycins / Q000008:administration & dosage* / Q000009:adverse effects; D009362:Neoplasm Metastasis; D010958:Plasminogen / Q000378:metabolism; D013997:Time Factors; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage* / Q000494:pharmacology
D003911:Dextrans; D005343:Fibrinolytic Agents; D008937:Mitomycins; D010958:Plasminogen; D008071:Lipoprotein Lipase; D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator